university of gothenburgGeneral description:

The University of Gothenburg has approximately 39,000 students and 5,000 employees. It is one of the major universities in northern Europe. It has places as one of its 8 strategic research areas, the patient-centred research concerning cardio-vascular disease including obesity, biomaterial and vaccines.

The department of Molecular and Clinical Medicine at the Institute of Medicine of the Sahlgrenska Academy at University of Gothenburg and the Sahlgrenska University Hospital focuses on hypothesis-driven, translational research in cardiovascular and metabolic disorders exemplified by clinical metabolic research in insulin resistance, obesity and cardiovascular diseases. The department strongly promotes innovative cross-disciplinary research and networks between basic medical and clinical sciences, bioinformatics, applied mathematics and industry. To create an infrastructure and environment that stimulate cooperation and synergies between scientists, state-of-the-art equipment platforms that are shared by all groups have been established. A strong aim is to attract, recruit and foster promising young basic and clinical scientists to launch successful careers in translational medicine. The research was recently evaluated by international experts and ranked as “outstanding and in some areas at the absolute forefront internationally”. The department consists of approximately 130 persons; including 12 professors. Most of the research groups are located either at the Wallenberg Laboratory for Cardiovascular Research, or in the closely located Lundberg Laboratory for Diabetes Research. The department houses the national strategic research center Sahlgrenska Center for Cardiovascular and Metabolic Research (CMR). Prof. Jan Borén is the chairman of the department and director of the CMR.



The cardiometabolic research area (obesity-insulin resistance and cardiovascular) has a long tradition and excellent quality and several of the groups are at the scientific forefront.


Equipment and competence for metabolic research including stable isotopes (glucose clamping, microdialysis, blood flow measurements in adipose tissue and muscle, indirect calorimetry and biopsies from adipose tissue and muscle), as well as equipment for molecular and histological analyses of tissue samples, cell lines and tissue.

Other EU Projects:

Dr Borén is a member of two ongoing EU project (Etherpath and LipidomicNet), and member of an IMI EMIF project planned to start late 2012.